{
    "clinical_study": {
        "@rank": "47058", 
        "arm_group": [
            {
                "arm_group_label": "PF-05175157", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a 6 week study to characterize the safety, tolerability and effects of PF-05175157\n      administered for 6 weeks in subjects with moderate to severe acne vulgaris."
        }, 
        "brief_title": "Study Of Safety, Tolerability And Effects Of PF-05175157 In Adults With Moderate To Severe Acne Vulgaris", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acne Vulgaris", 
        "condition_browse": {
            "mesh_term": "Acne Vulgaris"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males 18 years or older diagnosed with moderate to severe acne vulgaris who are\n             otherwise healthy.\n\n          -  Normal spirometry at screening (FEV1 and FVC (Forced Vital Capacity)at least 80%\n             predicted).\n\n          -  Minimum of 20 inflammatory lesions on the face.\n\n          -  Willing to discontinue other acne treatments prior to and during the study period\n             through follow-up.\n\n        Exclusion Criteria:\n\n          -  Subjects with active nodulocystic acne.\n\n          -  Subjects unwilling to comply with lifestyle guidelines, commit to study visits, and\n             perform study procedures.\n\n          -  History of dry eye or other known disease that affects the sclera or cornea.\n\n          -  History of pulmonary disease or inability to adequately perform testing."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02100527", 
            "org_study_id": "B1731019"
        }, 
        "intervention": [
            {
                "arm_group_label": "PF-05175157", 
                "description": "200 mg (as 2x100 mg tablets) twice a day (BID) for 6 weeks", 
                "intervention_name": "PF-05175157", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "placebo matching 200 mg (as 2x100 mg tablets) BID for 6 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "safety", 
            "tolerability", 
            "pharmacokinetics", 
            "oral dosing", 
            "moderate to severe acne vulgaris"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1731019&StudyName=Study%20Of%20Safety%2C%20Tolerability%20And%20Effects%20Of%20PF-05175157%20In%20Adults%20With%20Moderate%20To%20Severe%20Acne%20Vulgaris"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2a Randomized, Double-blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability And Effects Of PF-05175157 On Moderate To Severe Acne Vulgaris In Adult Subjects", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Physical examination, pulmonary function testing, adverse event monitoring, ECGs, vital signs, laboratory tests", 
            "measure": "Safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Weeks 2, 4, and 6"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02100527"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from baseline in amount and rate of sebum excretion", 
                "measure": "Sebum measurements", 
                "safety_issue": "No", 
                "time_frame": "Weeks 2, 4, and 6"
            }, 
            {
                "description": "Plasma concentrations", 
                "measure": "Pharmacokinetics of PF-05175157", 
                "safety_issue": "No", 
                "time_frame": "Weeks 2, 4, and 6"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014", 
        "why_stopped": "Study canceled"
    }
}